239 related articles for article (PubMed ID: 34899596)
1. Orbital Signaling in Graves' Orbitopathy.
Draman MS; Zhang L; Dayan C; Ludgate M
Front Endocrinol (Lausanne); 2021; 12():739994. PubMed ID: 34899596
[TBL] [Abstract][Full Text] [Related]
2. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
3. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
5. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
7. Pathogenic Phenotype of Adipogenesis and Hyaluronan in Orbital Fibroblasts From Female Graves' Orbitopathy Mouse Model.
Görtz GE; Moshkelgosha S; Jesenek C; Edelmann B; Horstmann M; Banga JP; Eckstein A; Berchner-Pfannschmidt U
Endocrinology; 2016 Oct; 157(10):3771-3778. PubMed ID: 27552248
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.
Moshkelgosha S; So PW; Deasy N; Diaz-Cano S; Banga JP
Endocrinology; 2013 Sep; 154(9):3008-15. PubMed ID: 23900776
[TBL] [Abstract][Full Text] [Related]
9. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
[TBL] [Abstract][Full Text] [Related]
10. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit.
Zhang M; Ding X; Wu LP; He MQ; Chen ZY; Shi BY; Wang Y
Thyroid; 2021 Apr; 31(4):638-648. PubMed ID: 33076782
[No Abstract] [Full Text] [Related]
11. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
12. Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy.
Zhang L; Grennan-Jones F; Draman MS; Lane C; Morris D; Dayan CM; Tee AR; Ludgate M
J Clin Endocrinol Metab; 2014 Jul; 99(7):E1183-90. PubMed ID: 24758182
[TBL] [Abstract][Full Text] [Related]
13. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
14. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
15. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.
Turcu AF; Kumar S; Neumann S; Coenen M; Iyer S; Chiriboga P; Gershengorn MC; Bahn RS
J Clin Endocrinol Metab; 2013 May; 98(5):2153-9. PubMed ID: 23482611
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
17. Immunological Aspects of Graves' Ophthalmopathy.
Łacheta D; Miśkiewicz P; Głuszko A; Nowicka G; Struga M; Kantor I; Poślednik KB; Mirza S; Szczepański MJ
Biomed Res Int; 2019; 2019():7453260. PubMed ID: 31781640
[TBL] [Abstract][Full Text] [Related]
18. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
19. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
